Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Table 7 Change from baseline to day 180 in serum and synovial fluid biomarkers

Matrix	Parameter reduction	Day	Placebo (n)	GC (n)	UC-II (n)
Serum	COMP (ng/mL)	180	−51.2 ± 31.3 (53)	−56.5 ± 36.0 (56)	−69.6 ± 40.8 (53)
Serum	CRP (mg/L)	180	15.1 ± 6.33 (26)	9.09 ± 5.36 (28)	13.0 ± 4.64 (28)
Synovial	IL-6 (ng/mL)	180	−9.54 ± 4.83 (23)	−9.72 ± 5.28 (24)	−11.8 ± 5.37 (21)
Synovial	MMP-3 (μg/mL)	180	−2.24 ± 1.26 (25)	−0.93 ± 0.79 (27)	−2.67 ± 1.85 (23)

Values presented as Mean ± SE. Statistical analysis was performed on log transformed and baseline adjusted values. No significant differences were observed between the study groups (p > 0.05)